WeTrials

A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)

What is this study?

This study is testing an experimental cancer medicine called EZN-2208, both by itself and combined with another medication called cetuximab, for people with colorectal cancer that has spread. Researchers want to see how well these treatments work and how safe they are for patients.

Who can participate?

You may be able to join if you have advanced colon or rectal cancer that has already been treated with standard chemotherapy drugs without success. Your eligibility will also depend on the specific genetic makeup of your tumor.

What will happen?

Depending on your tumor's genetics, you will receive either the experimental medicine alone, a combination of medicines, or a standard care treatment. Your health and cancer will be closely monitored during and after your treatment period.

Where and when?

This study has locations in Arizona and California, and its current status is listed as unknown, so we recommend reaching out to confirm if they are actively enrolling.

Key Points
  • 1Tests the experimental drug EZN-2208 for advanced colorectal cancer
  • 2Requires previous treatment with standard chemotherapy medications
  • 3Treatment groups are assigned based on your tumor's genetic profile

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Colorectal Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.